**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel in the order listed on Form Page 2.

Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

|  |  |
| --- | --- |
|  |  |
| NAMEDana Kimball Andersen | POSITION TITLEProfessor of Surgery, Johns Hopkins University School of Medicine (retired 2010) |

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.*)

|  |  |  |  |
| --- | --- | --- | --- |
| INSTITUTION AND LOCATION | DEGREE(*if applicable*) | YEAR(s) | FIELD OF STUDY |
| Duke University, Durham, NCDuke Univ. School of Medicine, Durham, NCDuke University Medical Center, Durham, NC | A.B.M.D. Residency | 19681972 1972-74, 1976-79  | ChemistryMedicineInternal MedicineGeneral Surgery |

1. **Positions and Honors.**

Clinical Associate in Endocrinology and Metabolism, Clinical Physiol Branch, GRC, NIA, NIH 1974-1976

Visiting Physician, Division of Gastroenterology, Baltimore City Hospitals, Baltimore, MD 1974-1976

Fellow (Instructor) in Surgery, Department of Surgery, Duke University Medical Center 1979-1980

Assistant, Associate, and Full Professor of Surgery and Medicine, State University of New York,

Health Science Center at Brooklyn 1980-1989

Attending Physician, State University Hospital and Kings County Hospital Center,

 State University of New York, Health Science Center at Brooklyn 1980-1989

Consultant in Surgery, Veterans Administration Medical Center, Brooklyn NY 1982-1989

Professor of Surgery and Medicine, The University of Chicago 1990-1994

Attending Physician, The University of Chicago Hospitals and Clinics, Chicago, IL 1990-1994

Professor and Vice-Chair of Surgery, Yale University School of Medicine 1994-2001

Attending Physician, Yale-New Haven Hospital, New Haven, CT 1994-2001

Consultant in Surgery, Veterans Affairs Medical Center, West Haven, CT 1994-2001

Haidak Professor and Chair, Department of Surgery, University of Massachusetts Medical 2001- 2004

 School and UMass Memorial Healthcare, Inc

Professor and Vice-Chair, Dept of Surgery, Johns Hopkins Univ School of Medicine, and 2005-2010

 Surgeon-in-Chief, Johns Hopkins Bayview Medical Center

# President, Medical Staff, Johns Hopkins Bayview Medical Center 2008-2010

# Honors and Awards

Alpha Omega Alpha, Duke University School of Medicine 1971

American Surgical Association, Foundation Fellowship Award 1982-1984

Society of Sigma Xi, Downstate Medical Center 1984

Golden Apple Teaching Award 1987

President, Association for Academic Surgery 1990

Master of Arts (Privatim) Yale University 1996

American Pancreatic Association, State-of-the-Art Lecturer 2005

“Best of the ADA” Presenter, at American Diabetes Association – Chinese Medical 2009

 Association Combined Meeting, Beijing, China

### **NIH Study Section Membership**

GM PO1 Site Visits 1985-1990

 Surgery and Bioengineering (Surg B)

 Ad Hoc Member 1991-1992

 Member 1993-95, 1998-2001

1. **Selected publications (in chronological order, from over 200 citations).**

McMahon, EM, DK Andersen, JM Feldman, S Schandberg. Methamphetamine-induced insulin release.

Science 1971; 174: 66-68.

Andersen, DK, D Elahi, JD Tobin, R Andres. Oral glucose augmentation of insulin secretion: Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 1978; 62: 152-161.

Elahi, D, DK Andersen, JC Brown, HT Debas, RJ Hershcopf, GS Raizes, JD Tobin, R Andres. Pancreatic alpha- and beta-cell responses to gastric inhibitory polypeptide infusion in normal man. Am J Physiol 1979; 237 (2): E185-191.

Putnam, WS, DK Andersen, RS Jones, HE Lebovitz. Selective potentiation of insulin mediated glucose disposal in normal dogs by the sulfonylurea glipizide. J Clin Invest 1981; 67: 1016-1023.

Elahi, D, DK Andersen, JD Tobin, R Andres. Discrepant performance on oral and intravenous glucose tolerance tests: The role of gastric inhibitory polypeptide. J Clin Endocrinol Metab 1981; 52: 1119-1203.

Elahi, D, DK Andersen, DC Muller, JD Tobin, JC Brown, R Andres. The enteric enhancement of glucose stimulated insulin release. The role of GIP in aging, obesity, and non-insulin dependent diabetes mellitus. Diabetes 1984: 33; 950-957.

Sun, YS, FC Brunicardi, P Druck, S Walfisch, SA Berlin, RE Chance, RL Gingerich, D Elahi, DK Andersen. Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg 1986: 151; 130-140.

Brunicardi, FC, RJ Goulet, YS Sun, SA Druck, D Berlin, D Elahi, DK Andersen. Splanchnic neural regulation of insulin and glucagon release in the isolated perfused human pancreas. Am J Surg 1987: 153; 34-40.

Brunicardi, FC, P Druck, YS Sun, D Elahi, RL Gingerich, DK Andersen. Regulation of pancreatic polypeptide secretion in the isolated perfused human pancreas. Am J Surg 1988: 155; 63-68.

Seymour, NE, FC Brunicardi, RL Chaiken, HE Lebovitz, RE Chance, RL Gingerich, D Elahi, DK Andersen. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery 1988: 104; 119-129.

Goldstein, JA, JD Kirwin, NE Seymour, JD Trachtenberg, EA Rademaker, DK Andersen. Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide administration in the rat. Surgery 1989: 106; 1128-1133.

Elahi, D, BA Clark, M McAloon-Dyke, GA Wong, RS Brown, ME Shapiro, KL Minaker, TL Flanagan, TL Pruett, RL Gingerich, JB Hanks, DK Andersen. Islet-cell responses to glucose in the human transplanted pancreas. Am J Physiol 1991: 261; E800-E808.

Elahi, D, M McAloon-Dyke, NK Fukagawa, GS Meneilly, AL Sclater, KL Minaker, JF Habener, DK Andersen. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Peptides 1994; 51: 63-74.

Andersen, DK, CL Ruiz, CF Burant. Insulin regulation of hepatic glucose transporter protein (GLUT2) is impaired in chronic pancreatitis. Ann Surg 1994; 219: 679-687.

Brunicardi, FC, RC Chaiken, AS Ryan, NE Seymour, JA Hoffmann, HE Lebovitz, RE Chance, RL Gingerich, DK Andersen, D Elahi. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996; 81: 3566-72.

Seymour NE, SA Spector, DK Andersen, MS Elm, DC Whitcomb. Hepatic pancreatic polypeptide receptors are overexpressed in chronic pancreatitis. J Surg Res 1998; 76: 47-52.

Dresner A, D Laurent, M Marcucci, ME Griffin, S Dufour, GW Cline, LA Slezak, DK Andersen, RS Handal, DL Rothman, KF Petersen, GI Shulman. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.

Slezak LA, AS Quinn, KC Sritharan, JP Wang, G Aspelund, DJ Taatjes, DK Andersen. Binding forces of hepatic microsomal and plasma membrane proteins in normal and pancreatic rats: An AFM force spectroscopic study. Microsco Res Tech 1999; 44: 363-367.

Maker AV, LA Slezak, G Aspelund, KC Stritharan, BP Jena, DK Andersen. Impaired phosphorylation of hepatic insulin receptor and glucose transporter proteins in chronic pancreatitis. Surg Forum 1999; 50: 14-16.

Xue C, G Aspelund, KC Sritharan, JP Wang, LA Slezak, DK Andersen. Isolated hepatic cholinergic denervation impairs glucose and glycogen metabolism. J Surg Res 2000; 90: 19-25.

Aspelund G, JM Egan, LA Slezak, KC Sritharan, D Elahi, DK Andersen. Exendin-4 and glucagon-like peptide-1 improve glucose tolerance and induce islet cell growth in chronic pancreatitis in rats. Surg Forum 2000; 51: 40-42.

Nathan JD, PD Zdankiewicz, JP Wang, SA Spector, BP Jena, NE Seymour, JP Geibel, DK Andersen. Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis. Pancreas 2001; 22(2): 172-8.

Slezak LA, DK Andersen. Pancreatic resection: Effects on glucose metabolism. World J Surg 2001; 25(4): 452-60.

Andersen DK, MD Topazian, Pancreatic head excavation. A variation on the theme of duodenum-preserving pancreatic head resection. Arch. Surg 2004; 139: 375-379.

Kono T, XP Wang, WE Fisher, DK Andersen, FC Brunicardi. Pancreatic polypeptide (PP). In: L Martini (Ed), Encyclopedia of Endocrine Diseases Volume 3, San Diego, Elsevier. 2004; pp 488-96.

Aspelund G, MD Topazian, JH Lee, DK Andersen. Improved outcomes for benign disease with limited pancreatic head resection. J Gastrointest Surg 2005; 9: 400-09.

Yantiss RK, BA Woda, GR Fanger, M Falos, GF Whalen, H Tada, DK Andersen, KL Rock, K Dresser. KOC (K homology domain containing protein Overexpressed in Cancer): A novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Path 2005; 29: 188-95.

Eisenberg ML, AV Maker, LA Slezak, JD Nathan, KC Sritharan, BP Jena, JP Geibel, DK Andersen. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem 2005; 15: 51-58.

Fung, M, D Thompson, RJ Shapiro, GL Warnock, DK Andersen,D Elahi, GS Meneilly. Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes. Diab Res Clin Pract 2006: 74; 189-93.

Andersen, DK. Mechanisms and emerging treatments of the metabolic complications of chronic

pancreatitis. Pancreas 2007: 35; 1-15.

Elahi, D, JM Egan, RP Shannon, GS Meneilly, A Khatri, JF Habener, DK Andersen. Glucagon-like

peptide-1 (9- 36) amide, cleavage product of glucagon-like peptide-1 (7-36) amide, is a glucoregulatory

peptide. Obesity 2008: 16; 1501-09.

Andersen DK, Reber HA. Can cystic masses in the head of the pancreas be safely and adequately removed Without a Whipple resection? Pancreas 2009; 38: 721-7.

Gibson BR, P Galiatsatos, A Rabiee, L Eaton, R Abu-Hamdah, C Christmas, SM Milner, DK Andersen, D Elahi. Intensive insulin therapy confers a similar survival benefit in the Burn Intensive Care Unit as in the Surgical Intensive Care Unit. Surgery 2009; 146: 922-930.

Andersen, DK,CF Frey. The evolution of the surgical treatment of chronic pancreatitis. Ann Surg 2010; 251: 18-32.

Magruder JT, D Elahi, DK Andersen**.** Diabetes and pancreatic cancer: Chicken or egg? Pancreas 2011; 40: 339-351.

Cui YF, DK Andersen**.** Pancreatogenic diabetes: Special considerations for management. Pancreatology 2011; 11: 279-294.

Cui YF, D Elahi, DK Andersen**.** Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass. J Gastrointest Surg 2011; 15: 1879-1888.

Rabiee A, P Galiatsatos, R Salas-Carrillo, MJ Thompson, DK Andersen, D Elahi. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump treatment. J Diab Sci Technol 2011: (In Press).

1. **Research Support.** List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals of the projects and responsibilities of principal investigator identified above.

**COMPLETED**

Thomas A Pappas Charitable Foundation (no #) 2004-2005 10% (Co-PI)

Gene Expression Profiling in Pancreatic Cancer $100,000

 Goals: To elucidate genes and proteins as early biomarkers of pancreatic carcinoma

National Institutes of Health RO1-DK39950 1989-1999 30% (PI)

Surgery of the Pancreas: Effects on Glucose Metabolism $1,262,470 (Total)

Goals: To evaluate the regulation of insulin action, as mediated by insulin receptor and glucose transporter function, in target tissues such as the liver in models of pancreatogenic diabetes.

National Institutes of Health MO-1-RR0318 1985-1988 30% (project PI)

Treatment of Pancreatic Diabetes by Pancreatic Polypeptide (PP) $4,386,714 (Total)

 Administration (one of eight programs)

Goals: To evaluate the role of PP in the treatment of pancreatogenic diabetes.

American Diabetes Association Feasibility Grant (no #) 1985-1987 25% (PI)

Treatment of Pancreatic Diabetes by Pancreatic Polypeptide (PP) $44,070

 Administration

 Goals: To evaluate the role of PP in the treatment of pancreatogenic diabetes.

National Institutes of Health RO1-AM30336 1983-1986 30% (PI)

The Role of GIP in Glucose Metabolism $231,324

Goals: To evaluate the role of gut peptides in insulin release and action.

 Serono Laboratories Research Grant (no #) 1984-1985 15% (PI)

 Efficacy of Somatostatin in the Treatment of Upper GI Bleeding $59,000

 Goals: To assess feasibility and efficacy of somatostatin therapy in upper GI bleeding

American Surgical Association Foundation Fellowship Award (no #) 1982-1984 50% (PI)

The Role of GIP in Glucose Metabolism $50,000

 Goals: To evaluate the role of glucose-dependent insulinotropic polypeptide (GIP) in insulin release and action